Assessing the impact of elexacaftor/tezacaftor/ivacaftor on anxiety & depression symptom scores in adults with Cystic Fibrosis
Journal of Cystic Fibrosis · 2025
DOI: 10.1016/j.jcf.2024.07.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Minh Nguyen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Benzodioxoles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
The mental health effects of elexacaftor/tezacaftor/ivacaftor (ETI) on adults with CF are still uncertain with mixed findings from published studies. To systematically investigate the impact of ETI on symptoms of anxiety and depression in adults with CF, Generalized Anxiety Disorder-7 (GAD-7) and Patient Health Questionnaire (PHQ-9) scores were evaluated at baseline, 6 months, and 12 months post-ETI. Overall, GAD-7 and PHQ-9 scores improved at 6 months post-ETI, with a greater proportion of individuals experiencing a clinically significant improvement (vs. worsening) of their symptoms, which was sustained at 12 months. Factors influencing mental health outcomes included pre-existing psychiatric diagnoses and psychiatric medication use. In conclusion, although there was overall improvement in anxiety and depression symptoms post-ETI, approximately 10 % of individuals experienced clinically significant worsening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
- Adult Cystic Fibrosis Program, St. Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.
- Adult Cystic Fibrosis Program, St. Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada; Department of Pharmacy, St. Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.
- Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Centre for Heart Lung Innovation, St. Paul's Hospital and University of British Columbia, Vancouver, BC, C…
Zitieren
APA
Nguyen, M., MacDiarmid, P., Tanzler, A., Dagenais, R., Bevanda, C., & Quon, B. S. (2025). Assessing the impact of elexacaftor/tezacaftor/ivacaftor on anxiety & depression symptom scores in adults with Cystic Fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.07.008
Vancouver
Nguyen M, MacDiarmid P, Tanzler A, Dagenais R, Bevanda C, Quon BS. Assessing the impact of elexacaftor/tezacaftor/ivacaftor on anxiety & depression symptom scores in adults with Cystic Fibrosis. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2024.07.008
BibTeX
@article{Nguyen2025,
author = {Nguyen, Minh and MacDiarmid, Pat and Tanzler, April and Dagenais, Renée and Bevanda, Carolina and Quon, Bradley S},
title = {Assessing the impact of elexacaftor/tezacaftor/ivacaftor on anxiety & depression symptom scores in adults with Cystic Fibrosis},
journal = {Journal of Cystic Fibrosis},
year = {2025},
doi = {10.1016/j.jcf.2024.07.008}
}
EUVIMED